Overview ARREST PAD (Peripheral Arterial Disease) Status: Completed Trial end date: 2011-12-01 Target enrollment: Participant gender: Summary This trial will test the hypothesis that inflammation and insulin resistance contribute to reduced walking distance in subjects with intermittent claudication by impairing vascular reactivity and skeletal muscle metabolic function. Phase: Phase 2/Phase 3 Details Lead Sponsor: Brigham and Women's HospitalCollaborator: National Heart, Lung, and Blood Institute (NHLBI)Treatments: AtorvastatinAtorvastatin CalciumPioglitazone